Are you above the legal age to view this content in your province/state?

Want to invest in a new profitable growing industry?

FSD Pharma with the acquisition of 100% of the issued and outstanding shares of Lucid Psycheceuticals Inc. (“Lucid”). If there was ever a right moment to invest in a growing industry, that time is now! Lucid is a Canadian-based specialty psychedelic pharmaceutical company focused on the development of therapies to treat critical neurodegenerative diseases. The mental health industry is a multi billion dollar industry and FSD along with Lucid are making the right moves to be part of the future, will you?

Want to be part of this opportunity?

Don't miss out on the opportunity to invest in the future of the mental health industry.

FSD Pharma Breaks All-time Daily Volume Record and Continues to Make History

  •  Today there is no cure for Multiple Sclerosis (MS). FSD Pharma will attempt to change that for millions of suffering people. FSD’s proprietary compound Lucid-MS has shown promising results to reverse progressive MS, in several animal models.
  •  Strategically advancing drug candidate pipelines focused on novel and unique therapies for neurodegenerative and psychiatric disorders.
  •  Well-capitalized to pursue acquisitions that present compelling opportunities across the psychedelics and innovative biotech space focused on Total Brain Health.
  •  Unique CAP structure with over 150,000 shareholders as of July 29, 2021.
  •  Balance sheet is free of debt and has over US $43.2M in cash as of June 30, 2021.

Don't wait any longer, this is your opportunity to invest

Get more information on why to invest in FSD Pharma (CSE: HUGE NASDAQ: HUGE FRA: 0K9A) how to do it and why we recommend it. Sign up and get our investor deck PDF Document.